×
Request Free Sample ×

Kindly complete the form below to receive a free sample of this Report

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background

Asia Pacific Gastrointestinal Drugs Market

ID: MRFR/Pharma/0190-CR
106 Pages
Rahul Gotadki
October 2017

Asia-Pacific Gastrointestinal Drugs Market Research Report Information: By Drug Class (Acid Neutralizers, Laxatives & Antidiarrheal, Anti-Emetics, Antiulcer), Type Of Disease (Esophagus Diseases, Stomach Diseases, Intestinal Diseases, Rectum Diseases) Forecast till 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Asia Pacific Gastrointestinal Drugs Market Infographic
Purchase Options

Asia Pacific Gastrointestinal Drugs Market Summary

The Asia-Pacific Gastrointestinal Drugs market is projected to experience substantial growth from 9.69 USD Billion in 2024 to 22.5 USD Billion by 2035.

Key Market Trends & Highlights

Asia-Pacific Gastrointestinal Drugs Key Trends and Highlights

  • The market is expected to grow at a compound annual growth rate (CAGR) of 7.94% from 2025 to 2035.
  • By 2035, the market valuation is anticipated to reach 22.5 USD Billion, indicating robust demand for gastrointestinal therapies.
  • In 2024, the market is valued at 9.69 USD Billion, reflecting a solid foundation for future expansion.
  • Growing adoption of advanced therapeutic options due to increasing prevalence of gastrointestinal disorders is a major market driver.

Market Size & Forecast

2024 Market Size 9.69 (USD Million)
2035 Market Size 22.5 (USD Million)
CAGR (2025-2035) 7.94%

Major Players

Abbott, Allergan Plc, AstraZeneca, Eli Lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals

Key Companies in the Asia Pacific Gastrointestinal Drugs Market market include

Market Segmentation

Key Players

  • Pharmaceutical Companies
  • Medical Devices Companies
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Intended Audience

  • Pharmaceutical Companies
  • Medical Devices Companies
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Regional Analysis

  • Pharmaceutical Companies
  • Medical Devices Companies
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Figure: Asia-Pacific Gastrointestinal Drugs Market, by Region, 2016 (%)

  • Pharmaceutical Companies
  • Medical Devices Companies
  • Research and Development (R&D) Companies
  • Market Research and Consulting Service Providers
  • Potential Investors

Report Scope

Attribute/Metric Details
  Market Size   USD 14,868 Million
  CAGR   8.60%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Drug Class and Type of Disease
  Geographies Covered   China, India, Republic of Korea, and Rest of Asia
  Key Vendors   Abbott, Allergan Plc, AstraZeneca, Eli lilly Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Pfizer Inc, Valeant Pharmaceuticals
  Key Market Opportunities   Initiatives in the research and development of innovative and advanced drugs
  Key Market Drivers   Increasing prevalence of GI diseases, rising geriatric population, and increasing investment in research & development

Market Highlights

Author
Rahul Gotadki
Assistant Manager

He holds an experience of about 7+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. In addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives

Leave a Comment

Download Free Sample

Kindly complete the form below to receive a free sample of this Report

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization
Direct Access to Analyst
Deliverable Format
Platform Access
Discount on Next Purchase 10% 15% 15%
Printable Versions